🇺🇸 FDA
Patent

US 11185585

Methods and compositions for improving antiangiogenic therapy with anti-integrins

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 11185585 (Methods and compositions for improving antiangiogenic therapy with anti-integrins) held by The Regents of the University of California expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K2039/545, A61K39/39558